Studying vitamin D treatment in people on dialysis for kidney disease
Observes how cholecalciferol affects blood mineral and bone tests in adults on dialysis.
Plain-language title generated from the registry record
Registry title: Vitamin D in Dialysis Patients - Diagnostic and Therapeutic Management
Key facts
- Where
- Gdansk, PolandSee the site
Where in Poland
- Medical University Of GdanskGdansk, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University of Gdansk
- Trial code
- NCT06571344
- Record updated
- 26 August 2024
- Original description
The goal of this observational study is to learn about the effects of cholecalciferol administration, according to guidelines for the general population, on laboratory parameters of Chronic Kidney Disease-Mineral and Bone Disorder in dialysis patients, depending of the attained levels of vitamin D (25OH)D).Read full original descriptionShow less
Vitamin D in Dialysis Patients - Diagnostic and Therapeutic Management
The goal of this observational study is to learn about the effects of cholecalciferol administration, according to guidelines for the general population, on laboratory parameters of Chronic Kidney Disease-Mineral and Bone Disorder in dialysis patients, depending of the attained levels of vitamin D (25OH)D).
The main question it aims to answer is:
How does cholecalciferol affect calcium and phosphate metabolism parameters depending on the achieved levels of 25(OH)D?
Participants taking cholecalciferol as part of their regular medical care for CKD-MBD will have the laboratory result parameters observed for up to 4 years.
Inclusion: CKD stage 5,dialysed patients with vitamin D deficiency or insufficiency (level of 25(OH)D < 30 ng/mL).
Exclusion: treatment with calcimimetics; treatment with active forms of vitamin D3,; treatment with corticosteroids; dialysis time of less than 3 months; inadequately controled secondary hyperparathyroidism (iPTH>800pg/mL); parathyroidectomy; bilateral nephrectomy; lack of consent to take part in the study.